Thomas B Ottoboni

Title: Thomas B. Ottoboni: Innovator in Pharmaceutical Formulations

Introduction

Thomas B. Ottoboni is a distinguished inventor based in Belmont, California, with an impressive portfolio featuring 51 patents. His work primarily revolves around the development of pharmaceutical formulations, particularly those addressing significant medical challenges.

Latest Patents

Among his latest innovations are the methods of use of emulsion formulations of a neurokinin-1 (NK-1) receptor antagonist. These patents disclose novel pharmaceutical formulations suitable for parenteral administration, including intravenous administration. The formulations he has developed include both the NK-1 receptor antagonist and dexamethasone sodium phosphate, creating stable oil-in-water emulsions specifically designed for non-oral treatment of emesis. This work is especially pivotal for treating subjects undergoing highly emetogenic cancer chemotherapy, showcasing his commitment to improving patient care through innovative solutions.

Career Highlights

Throughout his career, Thomas has made significant contributions to the pharmaceutical industry, particularly in the fields addressing chemotherapy-related side effects. He has been associated with notable companies, including Heron Therapeutics, Inc. and Point Biomedical Corporation, where his expertise in drug formulation and delivery systems has been instrumental in the advancement of therapeutic options.

Collaborations

Thomas has collaborated with esteemed professionals such as Lee Ann Lynn Girotti and Han Han. These partnerships have enriched his research and development endeavors, leading to groundbreaking innovations in the pharmaceutical sector.

Conclusion

Thomas B. Ottoboni exemplifies the spirit of innovation in the pharmaceutical field. His extensive work on NK-1 receptor antagonists and related formulations reflects a deep understanding of medical needs and an unwavering dedication to enhancing treatment options for patients. As an inventor with a rich patent portfolio, he continues to make meaningful contributions to healthcare.